Filter posts

Blurred Lines: Investors Explain Their Re-Thinking of Traditional Private-Only or Public-Only Invest...

The recent expansion and acceleration of the biotech stock market has seen a new willingness …

Electroceuticals and Digital Drug Delivery: Neurological Stimulation and Beyond

Some of the most experienced executives in biotechnology have begun asking themselves, “Can we foresee …

Biotech CEOs Talk JOBS Act and IPO Experiences at 2014 BIO Investor Forum

The JOBS Act has contributed to a dramatic acceleration in new biotech IPOs since its …

Fireside Chat with Ken Drazan, MD, Head of Johnson & Johnson Innovation

Day one of the BIO Investor Forum featured a Fireside Chat with Ken Drazan, MD, …

T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets

New approaches in cancer immunology are achieving promising early-stage results through novel techniques for arming …

How to Pitch to Investors

To help biotechs wow the scores of venture investors attending the BIO Investor Forum conference …

The First-Ever BIO Latin America Conference a Major Success

The first-ever BIO Latin America Conference was a major success and will become an annual …

BIO 2015 – Call for Sessions Extended

It’s not too late to submit a session proposal for the 2015 BIO International Convention. …

Gates to contribute $50M for Ebola response

Bill Gates was on MSNBC’s Morning Joe to discuss the Gates Foundation’s contribution of $50 …

BIO Investor Forum Company Snapshot: Syntrix Biosystems

1.     What is your company’s lead product or technology? Omnitram (O-desmethyltramadol) is a novel  oral …